Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for degradation. “Insulin was discovered 100 years ago, and the insulin receptor was discovered 50 years ago,” Heiko Lickert told BioWorld. “Now we have a new insulin receptor, which degrades insulin.” Lickert is the senior author of the paper reporting the new insights into how inceptor works, which were published online in Nature Metabolism. Read More
In a presentation at the recent American Society of Hematology meeting in San Diego, Kite Pharma Inc. reported preclinical data for KITE-753, an autologous rapid manufactured anti-CD19/CD20 CAR T-cell therapy being developed for the treatment of B-cell malignancies. Read More
Cyrus Biotechnology Inc. has reported data on its engineered IdeS (IgG-degrading enzyme of S. pyogenes) protease for IgG-driven autoimmune disease, showing potent activity on repeat doses in a rabbit redosing model while eliciting no anti-drug antibodies. Read More
Gynecological cancers with amplifications in the CCNE1 gene, which encodes cyclin E1, usually exhibit resistance to standard therapies. Since cyclin-dependent kinase 2 (CDK2) is the primary partner of cyclin E, CDK2 inhibitors represent a potentially effective treatment strategy for these malignancies. Read More
Splicebio S.L. has gained IND clearance from the FDA for its lead program SB-007, a protein splicing gene therapy to address the root genetic cause of Stargardt disease. Read More
Pathogenic variants in the KCNT1 gene, which encodes potassium channel subfamily T member 1, cause a severe childhood developmental epileptic encephalopathy. Read More
Korean Research Institute of Bioscience and Biotechnology has synthesized compounds reported to be useful for the treatment of non-tuberculous mycobacterial infections. Read More
Researchers from State University of New Jersey (Rutgers) presented preclinical data for PW-507, a sigma-1 receptor antagonist being evaluated for the treatment of binge eating disorder. Read More
Cancervax Inc. has selected pancreatic ductal adenocarcinoma (PDAC) as one of its first targets for preclinical development using its novel universal cancer treatment (UCT) platform. Read More
Scientists at Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College have identified compounds reported to be useful for the treatment of cancer. Read More
Researchers from Inovio Pharmaceuticals Inc. described the protective effect exerted by INO-4500, a DNA vaccine produced using the Syncon technology, against lethal Lassa virus in nonhuman primates. Read More
AC Immune SA has divulged compounds acting as α-synuclein (SNCA) aggregation inhibitors reported to be useful for the treatment of multiple system atrophy (MSA), Parkinson’s dementia, Lewy body dementia, Alzheimer’s disease and Parkinson’s disease, among others. Read More
Polypid Ltd. has entered into a new research and development collaboration with Immunogenesis Inc. for the development of novel formulations utilizing Polypid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology and Immunogenesis’ potent STING agonist drug candidate to potentially enhance treatment for solid tumors. Read More
Previous research suggested that gram-negative bacteria may hold potential for cancer immunotherapy because they contain agonists for multiple immune receptors. Read More
